Evidence map›Paper›PMID 36582266›Full record

ArticlePatient preference and adherence2022

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study.

Sophia Dobischok, Rebecca K Metcalfe, Elizabeth Angela Matzinger, Kurt Lock, Scott Harrison, Scott MacDonald, Sherif Amara, Martin T Schechter, Nick Bansback, Eugenia Oviedo-Joekes

Abstract read
In one paragraph

Article in Patient preference and adherence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sophia DobischokCentre for Health Evaluation & Outcome Sciences, Providence Health Care, Vancouver, BC, Canada.ORCID 0000-0001-8039-6778
Rebecca K MetcalfeCentre for Health Evaluation & Outcome Sciences, Providence Health Care, Vancouver, BC, Canada.
Elizabeth Angela MatzingerCentre for Health Evaluation & Outcome Sciences, Providence Health Care, Vancouver, BC, Canada.
Kurt LockCentre for Health Evaluation & Outcome Sciences, Providence Health Care, Vancouver, BC, Canada.
Scott HarrisonProvidence Health Care, Providence Crosstown Clinic, Vancouver, BC, Canada.
Scott MacDonaldProvidence Health Care, Providence Crosstown Clinic, Vancouver, BC, Canada.
Sherif AmaraSafePoint Supervised Consumption Site, Fraser Health Authority, Surrey, BC, Canada.
Martin T SchechterCentre for Health Evaluation & Outcome Sciences, Providence Health Care, Vancouver, BC, Canada.
Nick BansbackCentre for Health Evaluation & Outcome Sciences, Providence Health Care, Vancouver, BC, Canada.
Eugenia Oviedo-JoekesCentre for Health Evaluation & Outcome Sciences, Providence Health Care, Vancouver, BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Injectable opioid agonist treatment (iOAT) is an effective treatment for opioid use disorder (OUD). To our knowledge, no research has systematically studied client preferences for accessing iOAT. Incorporating preferences could help meet the heterogenous needs of clients and make addiction care more person-centred. This paper presents a pilot study of a best-worst scaling (BWS) preference elicitation survey that aimed to assess if the survey was feasible and accessible for our population and to test that the survey could gather sound data that would suit our planned analyses. Patients and Methods: Current and former iOAT clients (n = 18) completed a BWS survey supported by an interviewer using a think-aloud approach. The survey was administered on PowerPoint, and responses and contextual field notes were recorded manually. Think-aloud audio was recorded on Audacity. Results: Clients' feedback fell into five categories: framing of the task, accessibility, conceptualization of attributes and levels, formatting, and behaviour predicting questions. Survey repetitiveness was the most consistent feedback. The data simulation showed that 100 responses should provide an adequate sample size. Conclusion: This pilot demonstrates the type of analysis that can be done with BWS in our population, suggests that such analysis is feasible, and highlights the importance of the interviewer and participant working side-by-side throughout the task.

Indexed as

best worst scalingdiacetylmorphinehydromorphoneinjectable opioid agonist treatmentopioid agonist treatmentopioid use disorder

Identifiers

PMID36582266
PMCPMC9793789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.